Mr. Speaker, Ivermectin for use in humans is an oral drug approved in Canada for the treatment of certain parasitic worm infections, such as strongyloidiasis and onchocerciasis. This is based on evidence from clinical studies that were included by the manufacturer as part of its submission for review by Health Canada: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00498. However, Ivermectin is not approved for the prevention or treatment of coronavirus disease 2019, or COVID-19.
Health Canada was made aware of reports in media related to issues with the use of Ivermectin for COVID-19. Subsequently, the department communicated on this issue in a public advisory in August 2021 and October 2021: https://recalls-rappels.canada.ca/en/alert-recall/ivermectin-not-authorized-prevent-or-treat-covid-19-may-cause-serious-health-problems.
With regard to part (b), emerging information from sources such as literature publications and poison control centres was screened for signal detection purposes as part of our surveillance activities for products authorized to prevent or treat COVID-19. This specific publication was not reviewed by Health Canada as part of these activities given that it did not provide new risk or safety information with the use of Ivermectin as authorized and reflected in the product monograph for the drug.
With regard to part (c), Health Canada did not perform a risk-harm analysis for the use of Ivermectin to prevent or treat COVID 19. Health Canada only performs this type of analysis if a marketing application for a drug has been submitted by a manufacturer. Health Canada has not received an application seeking the authorization of Ivermectin for the treatment of COVID-19. Therefore, the department has not received nor reviewed any scientific evidence for the purpose of determining a benefits, harms and uncertainties profile on such use.